Hart, D. E., Gallagher, J. C., Puzniak, L. A., Hirsch, E. B., & Hirsch, E. B. (2019). 2281. Ceftolozane–tazobactam (C/T) Treatment Outcomes in Immunocompromised (IC) Patients with Multidrug-Resistant (MDR) Pseudomonas aeruginosa (PA) Infections. Open Forum Infect Dis.
Citación estilo ChicagoHart, Delaney E., Jason C. Gallagher, Laura A. Puzniak, Elizabeth B. Hirsch, and Elizabeth B. Hirsch. "2281. Ceftolozane–tazobactam (C/T) Treatment Outcomes in Immunocompromised (IC) Patients With Multidrug-Resistant (MDR) Pseudomonas Aeruginosa (PA) Infections." Open Forum Infect Dis 2019.
Cita MLAHart, Delaney E., et al. "2281. Ceftolozane–tazobactam (C/T) Treatment Outcomes in Immunocompromised (IC) Patients With Multidrug-Resistant (MDR) Pseudomonas Aeruginosa (PA) Infections." Open Forum Infect Dis 2019.